Fruquintinib, a multi-kinase inhibitor targeting VEGFR1/2/3, has received FDA approval for treating metastatic CRC and is presently undergoing phase-3 clinical trials for evaluating its efficacy against lung cancer (NCT02691299) (Dasari et al, 2023; Sun et al, 2014). This evidence concerns the gene FLT1 and lung carcinoma.